Holy Spirit News

Doctors at Holy Spirit Hospital Perform United States’ First Non-Trial TAVR Procedure using the SAPIEN device

Posted: December 14th, 2011

Rajesh Dave, MD, FACC, FSCAI, Chief Medical Executive, Holy Spirit Cardiovascular Institute, and Director, Cardiac Catheterization Laboratories at The Ortenzio Heart Center at Holy Spirit, and Vincent Park, MD, Cardiovascular Surgical Institute, together successfully performed the United States’ first (non-trial, commercial use) transcatheter aortic valve replacement (TAVR) using the Edwards Lifesciences’ SAPIEN device at Holy Spirit Hospital. The U.S. Food and Drug Administration (FDA) approved the Edwards SAPIEN Transcatheter Heart Valve Model 9000TFX and accessories for commercial use on November 2, 2011.

Read More | 0 comments